<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03040141</url>
  </required_header>
  <id_info>
    <org_study_id>VIS410-203</org_study_id>
    <nct_id>NCT03040141</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Safety of IV VIS410 Plus Oseltamivir Versus Oseltamivir Alone in Hospitalized Adults With Influenza A Infection Requiring Oxygen Support</brief_title>
  <official_title>Phase 2b, Multicenter, Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of Intravenous VIS410 in Addition to Oseltamivir (Tamiflu®) Compared With Oseltamivir Alone in Hospitalized Adults With Influenza A Infection Requiring Oxygen Support</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Visterra, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Visterra, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to compare the efficacy and safety of VIS410 in combination with oseltamivir vs
      oseltamivir alone in severely ill subjects with influenza A infection requiring oxygen
      support.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is to compare the efficacy and safety of VIS410 in combination with oseltamivir vs
      oseltamivir alone in severely ill subjects with influenza A infection requiring oxygen
      support. Subjects will be followed for 56 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 3, 2018</start_date>
  <completion_date type="Actual">November 22, 2018</completion_date>
  <primary_completion_date type="Actual">November 22, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the effect of 2 dose levels of VIS410 + oseltamivir on clinical outcome as assessed by comparison of clinical status ordinal Day 7 scores between treatment groups, and between all VIS410 recipients vs placebo.</measure>
    <time_frame>14 days</time_frame>
    <description>Clinical status is measured daily for 14 days using a seven-level ordinal scale, subject status will be classified by the worst clinical outcome for which they qualify</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of 2 dose levels of a single intravenous (IV) dose of VIS410 when administered in combination with oseltamivir in hospitalized subjects with influenza A infection</measure>
    <time_frame>56 days</time_frame>
    <description>The proportion of subjects with AEs and SAEs following administration of VIS410</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to cessation of O2 support compared to oseltamivir alone among patients requiring supplemental oxygen therapy at the time of enrollment with baseline room air oxygen saturation of ≤92%.</measure>
    <time_frame>56 days</time_frame>
    <description>Time to cessation of O2 support resulting in a stable SpO2 by pulse oximetry. Stable SpO2 is defined as two consecutive SpO2 values of &gt;92% on room air that are at least 8 hours apart.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of 2 dose levels of VIS410 + oseltamivir vs oseltamivir alone on viral titer in upper respiratory samples</measure>
    <time_frame>56 days</time_frame>
    <description>The difference between VIS410 + oseltamivir and oseltamivir alone treatment groups in peak viral load from nasopharyngeal swabs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of 2 dose levels of VIS410 + oseltamivir vs oseltamivir alone on resolution of viral load in upper respiratory samples</measure>
    <time_frame>56 days</time_frame>
    <description>The difference between VIS410 + oseltamivir and oseltamivir alone treatment groups in time to resolution of viral load from nasopharyngeal swabs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of 2 dose levels of VIS410 + oseltamivir vs oseltamivir alone on time to clinical response</measure>
    <time_frame>56 days</time_frame>
    <description>The difference between VIS410 + oseltamivir and oseltamivir alone treatment groups in time to clinical response defined as resolution of at least 4 of 5 vital signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of 2 dose levels of VIS410 + oseltamivir vs oseltamivir alone on time to cessation of ventilator support</measure>
    <time_frame>56 days</time_frame>
    <description>The difference between VIS410 + oseltamivir and oseltamivir alone treatment groups in total number of days on ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of 2 dose levels of VIS410 + oseltamivir vs oseltamivir alone on time to resumption of normal activities</measure>
    <time_frame>56 days</time_frame>
    <description>The difference between VIS410 + oseltamivir and oseltamivir alone treatment groups in the number of days to resumption of normal activities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of 2 dose levels of VIS410 + oseltamivir vs oseltamivir alone on all-cause and attributable 28- and 56- day mortality</measure>
    <time_frame>56 days</time_frame>
    <description>The difference between VIS410 + oseltamivir and oseltamivir alone treatment groups in all-cause and attributable mortality rates at Day 28 and 56</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of 2 dose levels of VIS410 + oseltamivir vs oseltamivir alone on time to alleviation of signs and symptoms of influenza as assessed by the FluPro Questionnaire at baseline and post-dose Kaplan Meier Analysis</measure>
    <time_frame>56 days</time_frame>
    <description>The difference between VIS410 + oseltamivir and oseltamivir alone treatment groups in the incidence, severity, and duration of signs and symptoms of influenza-like illness as assessed by the FluPRO Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of 2 dose levels of VIS410 + oseltamivir vs oseltamivir alone on the proportion of subjects with new documented bacterial pneumonia/superinfection</measure>
    <time_frame>56 days</time_frame>
    <description>The difference between VIS410 + oseltamivir and oseltamivir alone treatment groups in the percentage of subjects with new bacterial pneumonia/superinfection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of 2 dose levels of VIS410 + oseltamivir vs oseltamivir alone on the proportion of subjects with influenza-related complications</measure>
    <time_frame>56 days</time_frame>
    <description>The difference between VIS410 + oseltamivir and oseltamivir alone treatment groups in the percentage of subjects with influenza-related complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of 2 dose levels of VIS410 + oseltamivir vs oseltamivir alone on the immunogenicity of VIS410</measure>
    <time_frame>56 days</time_frame>
    <description>The difference between VIS410 + oseltamivir and oseltamivir alone treatment groups in the titer of anti-VIS410 antibody positive samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of 2 dose levels of VIS410 + oseltamivir vs oseltamivir alone on the emergence of resistance to VIS410 and oseltamivir</measure>
    <time_frame>56 days</time_frame>
    <description>Genotypic and/or phenotypic assessments to determine the emergence of VIS410 and oseltamivir-resistant viruses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of VIS410 in Serum</measure>
    <time_frame>56 days</time_frame>
    <description>Assess blood/serum samples to determine concentration of VIS410</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">89</enrollment>
  <condition>Influenza A</condition>
  <arm_group>
    <arm_group_label>VIS410 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intravenous infusion of fixed low dose of VIS410 in addition to oseltamivir</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VIS410 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intravenous infusion of fixed high dose of VIS410 in addition to oseltamivir</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single intravenous infusion of placebo in addition to oseltamivir</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose of VIS410</intervention_name>
    <description>Single intravenous infusion of fixed low dose of VIS410 in addition to oseltamivir</description>
    <arm_group_label>VIS410 low dose</arm_group_label>
    <other_name>oseltamivir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High dose of VIS410</intervention_name>
    <description>Single intravenous infusion of fixed high dose of VIS410 in addition to oseltamivir</description>
    <arm_group_label>VIS410 high dose</arm_group_label>
    <other_name>oseltamivir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single intravenous infusion of placebo in addition to oseltamivir</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>oseltamivir</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects aged ≥ 18 years.

          -  Test positive for influenza A by rapid antigen test or with another commercially
             available test on an adequate nasopharyngeal specimen in accordance with the
             manufacturer's instructions, or an acceptable local test, including PCR, FIA, or ELISA

          -  Onset of influenza symptoms no more than 5 days before VIS410/placebo infusion;
             symptoms may include cough, dyspnea, sore throat, fever, myalgias, headache, nasal
             symptoms (rhinorrhea, congestion), fatigue, diarrhea, anorexia, nausea, and vomiting.

          -  Requirement for oxygen support including any positive pressure ventilation

          -  Women of childbearing potential must have a negative pregnancy test within 2 days
             prior to VIS410/placebo infusion.

          -  Women should fulfill one of the following criteria:

               -  Post-menopausal; either amenorrhea ≥ 12 months or follicle stimulating hormone &gt;
                  40 mIU/mL as documented in their medical history

               -  Surgically sterile; hysterectomy, bilateral oophorectomy, or tubal ligation

               -  Women of childbearing potential participating in heterosexual sexual relations
                  must be willing to use adequate contraception from screening until 60 days post
                  VIS410/placebo infusion.

          -  Non-vasectomized (or vasectomized less than 6 months prior to dosing) male subjects
             who have a female partner of childbearing potential must use an effective birth
             control method from screening until 60 days post VIS410/placebo infusion.

          -  Subject, or a legally acceptable representative (LAR), is able to understand the
             purpose and risks of the study and willing to give voluntary written informed consent.

        Exclusion Criteria:

          -  Known or suspected intolerance or hypersensitivity to VIS410, oseltamivir,
             pretreatment medications (diphenhydramine, or to both ibuprofen and acetylsalicylic
             acid [ASA]), or closely related compounds (eg, other monoclonal antibodies)

          -  Subjects who have received VIS410 in the past

          -  History of receiving monoclonal antibody products (including VIS410) within 3 months
             prior to VIS410/placebo dosing or planned administration during the study period

          -  Subjects who have taken more than 6 doses of an approved antiviral therapy for
             influenza within the prior 96 hours (eg, oral oseltamivir, inhaled zanamivir, IV
             peramivir, or oral ribavirin) between onset of symptoms and VIS410/placebo dosing

          -  Subjects with known co-infection with influenza B or other viral respiratory
             infections (e.g., respiratory syncytial virus, parainfluenza viruses, respiratory
             adenoviruses)

          -  Subjects with lung transplant or history of severe chronic lung disease, including
             cystic fibrosis or any condition requiring home oxygen therapy

          -  Subjects on extracorporeal membrane oxygenation (ECMO) at time of randomization

          -  Subjects with end stage renal disease who are not undergoing hemodialysis

          -  Subjects with active graft-vs-host disease, hematopoietic stem cell transplant within
             the previous 90 days, or human immunodeficiency virus infection with a CD4 cell count
             of less than 200 per cubic millimeter

          -  Hospitalization for &gt; 48 hours prior to randomization

          -  High probability of mortality within 48 hours of randomization as determined by the
             Investigator

          -  Subjects weighing less than 45 kg

          -  Enrollment in any other investigational drug or device study, any disease or vaccine
             study within 30 days prior to Day 1 or within 5 half-lives of the investigational
             compound, whichever is longer

          -  Known or suspected alcohol or drug abuse, that is, abuse of a level that would
             compromise the safety or cooperation of the subject in the opinion of the Investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Oldach, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Visterra, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Blackfoot</city>
        <state>Idaho</state>
        <zip>83221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Butte</city>
        <state>Montana</state>
        <zip>59701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>York</city>
        <state>Pennsylvania</state>
        <zip>17405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Richland</city>
        <state>Washington</state>
        <zip>99352</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Melbourne</city>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Parkville</city>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>South Brisbane</city>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Westmead</city>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Woolloongabba</city>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Brest</city>
        <zip>224027</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Gomel</city>
        <zip>246029</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Gomel</city>
        <zip>246044</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Grodno</city>
        <zip>230017</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Grodno</city>
        <zip>230030</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Lesnoy</city>
        <zip>223041</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Minsk</city>
        <zip>220024</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Vitebsk</city>
        <zip>210009</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Kozloduy</city>
        <zip>3320</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Montana</city>
        <zip>3400</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Sofia</city>
        <zip>1233</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Veliko Tarnovo</city>
        <zip>5000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1C 6Z8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Pärnu</city>
        <zip>80010</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Tallinn</city>
        <zip>10138</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Tallinn</city>
        <zip>10617</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Tallinn</city>
        <zip>113419</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Tartu</city>
        <zip>51014</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <zip>85000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>La Tronche</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Limoges</city>
        <zip>87000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Metz-Tessy</city>
        <zip>74370</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Quimper</city>
        <zip>29000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Tbilisi</city>
        <zip>0144</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Tbilisi</city>
        <zip>0159</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Tbilisi</city>
        <zip>0160</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Daugavpils</city>
        <zip>LV5417</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Liepāja</city>
        <zip>LV3414</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Riga</city>
        <zip>LV 1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Rēzekne</city>
        <zip>LV4600</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Valmiera</city>
        <zip>LV4201</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Ventspils</city>
        <zip>LV3601</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Alor Setar</city>
        <state>Kedah</state>
        <zip>05350</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Taiping</city>
        <state>Perak</state>
        <zip>34000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Kuala Lumpur</city>
        <state>Wilayah Persekutuan</state>
        <zip>50586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Auckland</city>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Auckland</city>
        <zip>2025</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Wellington</city>
        <zip>6021</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Arkhangel'sk</city>
        <zip>163045</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Kazan</city>
        <zip>420140</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630051</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Smolensk</city>
        <zip>214006</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Tomsk</city>
        <zip>634063</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Vladimir</city>
        <zip>600023</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Kragujevac</city>
        <zip>34000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Niš</city>
        <zip>18000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Novi Sad</city>
        <zip>21000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Singapore</city>
        <zip>119228</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Singapore</city>
        <zip>308433</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Lyttelton</city>
        <state>Centurion</state>
        <zip>0157</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Auckland Park</city>
        <state>Gauteng</state>
        <zip>2006</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0002</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Thabazimbi</city>
        <state>Limpopo</state>
        <zip>0380</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Benoni</city>
        <zip>1501</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Cape Town</city>
        <zip>7570</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Durban</city>
        <zip>4092</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Worcester</city>
        <zip>6850</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Badalona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Barakaldo</city>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Granada</city>
        <zip>18016</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Terrassa</city>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Bangkok</city>
        <zip>10110</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Mueang Nonthaburi</city>
        <zip>11000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Ankara</city>
        <zip>06230</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Istanbul</city>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Trabzon</city>
        <zip>61080</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Ivano-Frankivs'k</city>
        <zip>76008</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Kyiv</city>
        <zip>01133</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Kyiv</city>
        <zip>04112</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Odesa</city>
        <zip>65023</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Poltava</city>
        <zip>36038</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Sumy</city>
        <zip>40021</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visterra</name>
      <address>
        <city>Zhytomyr</city>
        <zip>10002</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belarus</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Georgia</country>
    <country>Latvia</country>
    <country>Malaysia</country>
    <country>New Zealand</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Singapore</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Thailand</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>January 23, 2017</study_first_submitted>
  <study_first_submitted_qc>January 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2017</study_first_posted>
  <last_update_submitted>November 6, 2019</last_update_submitted>
  <last_update_submitted_qc>November 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oseltamivir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

